转移性-话题@MedSci

#转移性#

975篇内容 | 3580人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1386696, encodeId=32361386696b6, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Nat Commun：GD2-B7H3 SynNotch CAR-T在转移性神经母细胞瘤中的临床前评估, objectType=article, longId=206277, objectId=56be2062e7d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56be2062e7d0, replyNumber=0, likeNumber=69, createdTime=2021-01-28, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56be2062e7d0, moduleTitle=Nat Commun：GD2-B7H3 SynNotch CAR-T在转移性神经母细胞瘤中的临床前评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56be2062e7d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386695, encodeId=cbb4138669553, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Br J Cancer：CirCe01随机试验分析基于循环肿瘤细胞的化疗监测策略对于转移性乳腺癌患者的临床实用性, objectType=article, longId=206263, objectId=fb48206263fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb48206263fd, replyNumber=0, likeNumber=77, createdTime=2021-01-27, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb48206263fd, moduleTitle=Br J Cancer：CirCe01随机试验分析基于循环肿瘤细胞的化疗监测策略对于转移性乳腺癌患者的临床实用性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb48206263fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386694, encodeId=7bb9138669400, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Nat Med：转移性乳腺癌中Durvalumab与维持化疗的疗效比较, objectType=article, longId=206034, objectId=c40a2060347b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c40a2060347b, replyNumber=0, likeNumber=105, createdTime=2021-01-23, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c40a2060347b, moduleTitle=Nat Med：转移性乳腺癌中Durvalumab与维持化疗的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c40a2060347b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386693, encodeId=624c13866930c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Eur Urol Oncol：选择转移性肾细胞癌患者中进行减瘤性肾切除术的更佳候选者的一种新的风险评分开发, objectType=article, longId=205986, objectId=3fd020598612, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fd020598612, replyNumber=0, likeNumber=90, createdTime=2021-01-23, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fd020598612, moduleTitle=Eur Urol Oncol：选择转移性肾细胞癌患者中进行减瘤性肾切除术的更佳候选者的一种新的风险评分开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fd020598612)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386692, encodeId=027b13866926d, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Clin Cancer Res：转移性乳腺癌的新基因组学特征！, objectType=article, longId=205960, objectId=3d0020596053, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d0020596053, replyNumber=0, likeNumber=63, createdTime=2021-01-22, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d0020596053, moduleTitle=Clin Cancer Res：转移性乳腺癌的新基因组学特征！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d0020596053)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386691, encodeId=678a13866912b, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Ann Oncol：3期| 帕博西尼+内分泌治疗 vs 化疗用于ER+HER2-芳香化酶抑制剂耐药的转移性乳腺癌, objectType=article, longId=205891, objectId=075d205891cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=075d205891cb, replyNumber=0, likeNumber=74, createdTime=2021-01-21, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=075d205891cb, moduleTitle=Ann Oncol：3期| 帕博西尼+内分泌治疗 vs 化疗用于ER+HER2-芳香化酶抑制剂耐药的转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=075d205891cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386690, encodeId=1a0f1386690cf, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=JCO：北大肿瘤医院3期试验揭示多科室联合治疗转移性胃癌的临床获益, objectType=article, longId=205673, objectId=6fbf2056e3fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fbf2056e3fc, replyNumber=0, likeNumber=80, createdTime=2021-01-14, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fbf2056e3fc, moduleTitle=JCO：北大肿瘤医院3期试验揭示多科室联合治疗转移性胃癌的临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fbf2056e3fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386689, encodeId=784913866898d, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet Oncol：CD40激动性单克隆抗体APX005M联合化疗治疗转移性胰腺癌, objectType=article, longId=205427, objectId=c5f320542e03, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5f320542e03, replyNumber=0, likeNumber=63, createdTime=2021-01-08, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5f320542e03, moduleTitle=Lancet Oncol：CD40激动性单克隆抗体APX005M联合化疗治疗转移性胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5f320542e03)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386688, encodeId=57e3138668859, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet oncol：寡颅外转移性实体瘤患者采用立体定向消融体部放射治疗的预后, objectType=article, longId=205425, objectId=9a502054250b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a502054250b, replyNumber=0, likeNumber=57, createdTime=2021-01-08, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a502054250b, moduleTitle=Lancet oncol：寡颅外转移性实体瘤患者采用立体定向消融体部放射治疗的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a502054250b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386687, encodeId=8c2d138668ef5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle= J Clin Oncol：Capivasertib联合多西他赛和泼尼松龙治疗转移性去势抵抗性前列腺癌, objectType=article, longId=204950, objectId=4b6d204950d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b6d204950d0, replyNumber=0, likeNumber=79, createdTime=2020-12-30, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b6d204950d0, moduleTitle= J Clin Oncol：Capivasertib联合多西他赛和泼尼松龙治疗转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b6d204950d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386686, encodeId=ec231386686c0, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究, objectType=article, longId=204948, objectId=3cf1204948c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cf1204948c8, replyNumber=0, likeNumber=17, createdTime=2020-12-30, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cf1204948c8, moduleTitle=患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cf1204948c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386685, encodeId=c1c0138668596, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Eur Urol：锕-225-PSMA-617在镥-177-PSMA治疗失败后的晚期转移性去势抵抗性前列腺癌中的活性和不良反应 , objectType=article, longId=204687, objectId=679620468e97, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=679620468e97, replyNumber=0, likeNumber=83, createdTime=2020-12-21, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=679620468e97, moduleTitle=Eur Urol：锕-225-PSMA-617在镥-177-PSMA治疗失败后的晚期转移性去势抵抗性前列腺癌中的活性和不良反应 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=679620468e97)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386684, encodeId=1f35138668415, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=CHMP推荐曲妥珠单抗Deruxtecan治疗HER2阳性转移性乳腺癌, objectType=article, longId=204512, objectId=cc0e204512c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc0e204512c6, replyNumber=0, likeNumber=64, createdTime=2020-12-16, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc0e204512c6, moduleTitle=CHMP推荐曲妥珠单抗Deruxtecan治疗HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc0e204512c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386683, encodeId=5c6d1386683b7, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Radiology：转移性肾细胞癌化疗后有没有效如何看？, objectType=article, longId=204280, objectId=cf0020428046, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf0020428046, replyNumber=0, likeNumber=72, createdTime=2020-12-09, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf0020428046, moduleTitle=Radiology：转移性肾细胞癌化疗后有没有效如何看？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf0020428046)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386682, encodeId=541f1386682bd, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet：派姆单抗联合化疗一线治疗PD-L1阳性转移性三阴性乳腺癌, objectType=article, longId=204210, objectId=9f312042101b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f312042101b, replyNumber=0, likeNumber=73, createdTime=2020-12-08, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f312042101b, moduleTitle=Lancet：派姆单抗联合化疗一线治疗PD-L1阳性转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f312042101b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386681, encodeId=2f151386681c6, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Sci Rep：一线阿西替尼治疗纺锤组织学转移性肾细胞癌效果较差, objectType=article, longId=203908, objectId=cbca2039086d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbca2039086d, replyNumber=0, likeNumber=122, createdTime=2020-12-01, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbca2039086d, moduleTitle=Sci Rep：一线阿西替尼治疗纺锤组织学转移性肾细胞癌效果较差, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbca2039086d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386680, encodeId=c91013866804f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=NICE支持Braftovi治疗BRAF阳性转移性结直肠癌, objectType=article, longId=203872, objectId=e95e2038e2f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e95e2038e2f3, replyNumber=0, likeNumber=74, createdTime=2020-12-01, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e95e2038e2f3, moduleTitle=NICE支持Braftovi治疗BRAF阳性转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e95e2038e2f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386679, encodeId=6db213866e978, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Opdivo联合Yervoy：欧洲获批一线治疗转移性非小细胞肺癌, objectType=article, longId=203219, objectId=4e11203219e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e11203219e6, replyNumber=0, likeNumber=57, createdTime=2020-11-11, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e11203219e6, moduleTitle=Opdivo联合Yervoy：欧洲获批一线治疗转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e11203219e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386678, encodeId=e2a913866e871, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=NMPA批准XTANDI（恩杂鲁胺软胶囊）治疗非转移性去势抵抗性前列腺癌, objectType=article, longId=203137, objectId=f21a20313e8c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f21a20313e8c, replyNumber=0, likeNumber=69, createdTime=2020-11-10, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f21a20313e8c, moduleTitle=NMPA批准XTANDI（恩杂鲁胺软胶囊）治疗非转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f21a20313e8c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386677, encodeId=e71e13866e7f4, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=JAMA Oncology：一种新可以更好地预测非转移性前列腺癌患者预后的新分期系统, objectType=article, longId=202517, objectId=e79120251eaf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e79120251eaf, replyNumber=0, likeNumber=65, createdTime=2020-10-27, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e79120251eaf, moduleTitle=JAMA Oncology：一种新可以更好地预测非转移性前列腺癌患者预后的新分期系统, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e79120251eaf)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

转移性

2020-05-29

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Nat Commun：GD2-B7H3 SynNotch CAR-T在转移性神经母细胞瘤中的临床前评估

2021-01-28

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Br J Cancer：CirCe01随机试验分析基于循环肿瘤细胞的化疗监测策略对于转移性乳腺癌患者的临床实用性

2021-01-27

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Nat Med：转移性乳腺癌中Durvalumab与维持化疗的疗效比较

2021-01-23

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Eur Urol Oncol：选择转移性肾细胞癌患者中进行减瘤性肾切除术的更佳候选者的一种新的风险评分开发

2021-01-23

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Clin Cancer Res：转移性乳腺癌的新基因组学特征！

2021-01-22

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Ann Oncol：3期| 帕博西尼+内分泌治疗 vs 化疗用于ER+HER2-芳香化酶抑制剂耐药的转移性乳腺癌

2021-01-21

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

JCO：北大肿瘤医院3期试验揭示多科室联合治疗转移性胃癌的临床获益

2021-01-14

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet Oncol：CD40激动性单克隆抗体APX005M联合化疗治疗转移性胰腺癌

2021-01-08

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet oncol：寡颅外转移性实体瘤患者采用立体定向消融体部放射治疗的预后

2021-01-08

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

J Clin Oncol：Capivasertib联合多西他赛和泼尼松龙治疗转移性去势抵抗性前列腺癌

2020-12-30

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究

2020-12-30

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Eur Urol：锕-225-PSMA-617在镥-177-PSMA治疗失败后的晚期转移性去势抵抗性前列腺癌中的活性和不良反应

2020-12-21

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

CHMP推荐曲妥珠单抗Deruxtecan治疗HER2阳性转移性乳腺癌

2020-12-16

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Radiology：转移性肾细胞癌化疗后有没有效如何看？

2020-12-09

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet：派姆单抗联合化疗一线治疗PD-L1阳性转移性三阴性乳腺癌

2020-12-08

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Sci Rep：一线阿西替尼治疗纺锤组织学转移性肾细胞癌效果较差

2020-12-01

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

NICE支持Braftovi治疗BRAF阳性转移性结直肠癌

2020-12-01

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Opdivo联合Yervoy：欧洲获批一线治疗转移性非小细胞肺癌

2020-11-11

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

NMPA批准XTANDI（恩杂鲁胺软胶囊）治疗非转移性去势抵抗性前列腺癌

2020-11-10

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

JAMA Oncology：一种新可以更好地预测非转移性前列腺癌患者预后的新分期系统

2020-10-27

科室
- - 订阅+
  - 更多科室
工具
服务